Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors, an Open-label Single-center Phase I Clinical Trial

NCT06546150 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT06546150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06546150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors, an Open-label Single-center Phase I Clinical Trial
Lead sponsor
Henan Cancer Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
March 1, 2024
Completion date
April 1, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kras g12d, t cell therapy